Radiologische Diagnostik des multiplen Myeloms

Clinical/methodical issue

Robust and reliable imaging methods are required to estimate the skeletal tumor load in multiple myeloma, as well as for the diagnosis of extraskeletal manifestations. Imaging also plays an essential role in the assessment of fracture risk and of vertebral fractures.

Standard radiological methods

The conventional skeletal survey has been the gold standard in the imaging of multiple myeloma for many years.

Methodical innovations

Other modalities which have been investigated and are in use are whole-body computed tomography (WBCT), 18F-fluorodeoxyglucose positron emission tomography computed tomography (FDG PET-CT) and whole-body magnetic resonance imaging (WBMRI). These techniques are able to depict both mineralized bone and the bone marrow with a high sensitivity for myeloma lesions.

Performance

Several studies have shown that cross-sectional imaging is superior to the skeletal survey in the detection of myeloma lesions and WBMRI has been shown to be significantly more sensitive than WBCT for the detection of focal myeloma lesions as well as for diffuse infiltration. The FDG PET-CT technique has a sensitivity comparable to WBMRI.

Achievements

Due to the higher sensitivity in the detection of myeloma lesions WBCT and WBMRI should replace the skeletal survey.

Practical recommendations

A WBCT should be performed if there is suspicion of multiple myeloma. If no focal lesions are found WBMRI or at least MRI of the spine and pelvis should be additionally performed if available. If WBMRI has been initially performed and focal lesions are present, an additional WBCT may be performed to assess the extent of bone destruction and fracture risk. In cases of monoclonal gammopathy of undetermined significance (MGUS), solitary and smoldering myeloma, a WBMRI, if available, should be performed in addition to WBCT.     

Role of MRI for the diagnosis and prognosis of multiple myeloma

For the correct staging of patients with multiple myeloma sensitive detection is mandatory in order to estimate prognosis and to decide for adequate therapy. Magnetic resonance imaging (MRI) is superior to radiography for both, focal and diffuse involvement. Five different infiltration patterns can be differentiated: (1) normal appearance of bone marrow despite minor microscopic plasma cell infiltration, (2) focal involvement, (3) homogeneous diffuse infiltration, (4) combined diffuse and focal infiltration, (5) "salt-and-pepper"-pattern with inhomogeneous bone marrow with interposition of fat islands. For the fast and complete assessment of all patterns a combination of a T1-weighted spin echo sequence and a fat suppression technique should be employed. The focal involvement is clearly demonstrated as areas of high signal intensity on, e.g. STIR images. Diffuse involvement is best detected on unenhanced T1-weighted SE sequences and it manifests as homogeneous signal reduction. It can be quantified objectively by calculation of the percentage of signal intensity increase after contrast material injection. With parallel imaging and special coil devices, such as total imaging matrix (Siemens systems, Avanto) a "screening" of the whole red bone marrow as for myeloma infiltration is possible within a reasonable time. Patients without bone marrow infiltration have a significantly longer survival than patients with bone marrow infiltration in MRI at the time of diagnosis. However, even in stage I disease (Durie and Salmon) and negative X-ray films bone marrow infiltration in MRI may be detected in 29-50% of patients. Those patients typically show an earlier disease progression. Recently, MRI has been implemented in the clinical staging of patients with multiple myeloma. MRI may also monitor response to therapy. Signs of good response in cases with focal involvement are: reduction of signal intensity on T2-weighted spin echo images, lack or rim-like enhancement after contrast material injection or even a normalisation of bone marrow signal. In case of diffuse involvement a partly patchy reconversion to fatty marrow can be seen.     

Staging des multiplen Myeloms mit der MRT: Vergleich zur MSCT und zur konventionellen Röntgendiagnostik

The staging of patients with multiple myeloma demands sensitive imaging methods for the assessment of the skeletal system. MRI allows for direct visualization of the bone marrow which exhibits five different infiltration patterns in multiple myeloma: 1. normal appearance of the bone marrow, 2. focal involvement, 3. homogeneous diffuse infiltration, 4. combined diffuse and focal infiltration, 5. "salt and pepper" pattern with inhomogeneous bone marrow signals due to multiple fat islands. The combination of T1w-SE and STIR sequences is best suited for detecting all infiltration patterns and for the differential diagnoses e. g. hemangiomas. With parallel imaging in MRI, acquisition times can be markedly reduced and whole-body screening of the bone marrow can be achieved within 30 min. MRI is superior to radiography for the detection of focal as well as diffuse infiltration. Multidetector computed tomography and especially 16- and 64-detector row scanners allow fast imaging with thin slice collimation and multiplanar reconstructions. With low-dose protocols, effective dose reduction can be achieved, so that radiation exposure is only slightly higher than that of a whole-body skeletal x-ray exam. Sensitivity of MSCT is markedly superior to conventional radiography. Due to the direct visualization of the bone marrow with MRI, MRI is superior in detecting early infiltrations with myeloma cells without osteolyses. In advanced multiple myeloma, CT on the other hand, enables for more precise assessment of bony destructions and fracture risk.     

骶骨肿瘤的影像学诊断

目的比较X线平片、CT、MRI对骶骨肿瘤的诊断价值。方法回顾分析了25例骶骨肿瘤的各种影像学表现。结果平片能显示较明显的病变,有良好的空间分辨率;CT能显示较早期的病变,并清楚显示病变的结构与邻近组织关系;MRI可以及时发现病变,并能反映病变的组织成分,以及骨质和软组织受累的范围。结论对骶骨肿瘤的诊断,X线平片、CT和MRI各有特点。三者应互相结合,取长补短。     

Diagnostik des Plasmozytoms mit der MRT

Background. In multiple myeloma 5 different infiltration patterns can be differentiated: 1. normal appearance of bone marrow, 2. focal involvement, 3. homogeneous diffuse infiltration, 4. combined diffuse and focal infiltration, 5. “salt- and pepper” pattern with inhomogeneous bone marrow with interposition of fat islands. Methods. For the fast and total acquisition of all patterns a combination of a T1-weighted spin echo sequence and a fat suppression technique is superior. The focal involvement is clearly demonstrated as areas of high signal intensity on e. g. STIR images. Diffuse involvement can be quantified objectively by calculation of the percentage of signal intensity increase after contrast material injection. MRI is superior to X-ray in focal and diffuse involvement. With ultrafast sequences a “screening” of the whole red bone marrow as for myeloma infiltration is possible. Prognosis. In prognosis studies diffuse infiltration is inferior to focal involvement. Patients without bone marrow infiltration have a significantly longer survival than patients with bone marrow infiltration in MRI at the time of diagnosis. However, even patients in stage one of disease (Durie and Salmon) and negative X-ray films can show bone marrow infiltration in MRI. Those patients often show an early disease progression. Good response to therapy in focal involvement are: reduction of signal intensity on T2- weighted spin echo images, lack or rim- like enhancement after contrast material injection or even a normalisation of bone marrow signal. In case of diffuse involvement a partly patchy reconversion to fatty marrow can be seen.     

Diagnostic value of MRI in comparison to scintigraphy, PET, MS-CT and PET/CT for the detection of metastases of bone

The initial localization of metastases in the bone in patients with solid tumors has a relatively good prognosis in comparison with visceral metastasization. The early detection of bone marrow metastases allows for a rapid initiation of therapy and a subsequent reduction in the morbidity rate. Modern MRI is superior to the 30-year-old skeletal scintigraphy and bone marrow scintigraphy with respect to sensitivity, specificity, as well as the extent of osteal metastasis. MRI provides substantial, therapy-relevant additional information. MSCT plays an important role in the management of cancer patients in clinical routine and gives an excellent survey of the axial skeleton by demonstrating osteolytic and osteoblastic metastases. Extensive comparative studies of MRI with 18F-FDG-PET and 18F-fluoride-PET have not yet been carried out. Whole body MRI is a very promising new staging method for the oncological diagnosis of solid tumors and the detection of osteal metastases. The adoption of 18F-FDG-PET and 18F-fluoride-PET FDG as well as the side by side PET-CT image fusion and the two in one PET/CT examinations appears to be slightly less sensitive to whole body MRI in the detection of osteal metastases. Larger, prospective multicenter studies are necessary to establish these as new, promising methods for the detection of osteal metastases.     

多发性骨髓瘤MRI和X线诊断价值

目的　进一步研究多发性骨髓瘤 (multiplemyeloma ,MM )的MRI表现特点并与X线检查相比较其优缺点 ,同时探讨MRI分型与临床分期的联系。材料与方法　选择 19例经骨髓穿刺证实的MM患者的下胸椎至股骨上段行X线与MRI检查 ,对相同患者相同时间相同部位的X线平片与MRI表现、临床分期、MRI分型与骨髓浆细胞百分比进行比较。结果　MM的MRI据T1 WI骨髓信号减低的形态分为以下类型 :正常型 ,弥漫型 ,局灶型 ,混合型 ,“盐和胡椒”型。腰椎以弥漫型多见占 47.3% ,局灶型、混合型各占15 .8% ;骨盆及股骨近段以局灶型多见占 5 7.9% ,弥漫型占 2 1.1% ,无混合型。MM的X线表现 :未见异常 7例 ,骨质疏松的基础上病理性骨折或骨质破坏 12例。腰椎、骨盆及股骨近段各部位检查的阳性率MRI均为 84.2 % ,X线平片分别为 63.2 %、42 .1%和31.6%。MRI表现 :正常型及“盐和胡椒”型的病例其骨髓浸润较轻 ,均见于临床Ⅰ期MM ,其骨髓浆细胞的百分比较低 ( 8.4± 2 .5 ) ;而弥漫型、局灶型、混合型均见于Ⅱ、Ⅲ期MM ,其骨髓浸润程度相对较重 ,骨髓浆细胞的百分比较高 ( 30 .5± 6.7、45 .2± 11.2 )。结论　MM的MRI表现可分为正常型、弥漫型、局灶型、混合型、“盐和胡椒”型。MRI对MM的敏感性明显高于X线检查 ,但两者的特异性较差     

Multiples Myelom: Aktuelle Empfehlungen für die Bildgebung

CLINICAL/METHODICAL ISSUE: Imaging in monoclonal plasma cell disease serves to detect end organ damage, i.e., osteoporosis or bone destruction. Diffuse or circumscribed bone marrow infiltration without damage to mineralized bone is so far not regarded as end organ damage. STANDARD RADIOLOGICAL METHODS: Skeletal plain x-ray film survey to detect bone destruction, osteoporosis or fractures. METHODICAL INNOVATIONS: Whole body low-dose computed tomography (CT) and whole body magnetic resonance imaging (MRI) allow a more sensitive assessment of both mineralized bone and bone marrow, with greater patient comfort and in the case of MRI without ionizing radiation. PERFORMANCE: According to the literature, cross-sectional imaging is clearly superior to skeletal surveys and MRI is more sensitive than CT. Every locally destructive lesion will be detectable with MRI but for assessing the damage to mineralized bone CT is indispensible. The sensitivities of positron emission tomography (PET)/CT and MRI are comparable. ACHIEVEMENTS: If available whole body MRI and whole body low dose CT should replace conventional skeletal surveys. This has already been implemented in several centers in Germany. PRACTICAL RECOMMENDATIONS: For the initial diagnosis of monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma or symptomatic multiple myeloma, a whole-body MRI and a whole body low-dose CT should be performed. For MGUS and asymptomatic myeloma, whole body MRI only should be performed for follow-up until detection of first bone destruction. Patients with symptomatic multiple myeloma and known bone destruction will usually have whole body low-dose CT, supplemented by MRI studies where clinically required.     

MRI and CT evaluation of primary bone and soft-tissue tumors

Twenty-six patients with primary tumors of bone or somatic soft tissues underwent both magnetic resonance imaging (MRI) and computed tomography (CT); 15 of the patients had radionuclide bone scans as well. Only in a minority of cases did these tomographic methods provide information needed for diagnosis that could not be derived from the plain radiographs alone; however, for assessing the extent of the disease, both CT and MRI proved very valuable, particularly MRI. Specifically, MRI was superior to CT in delineating the extent of the neoplasms and their relation to surrounding structures in 21 of the patients, equal in four, and inferior in only one. Furthermore, in the 13 patients with tumors of long bone, MRI was judged superior to CT in visualizing marrow abnormality in 12 cases, and equal in only one case. Radionuclide scans demonstrated the lesions in 14 of the 15 cases; its primary utility was in excluding additional lesions. It is concluded that for these patients, MRI was the imaging method of choice in assessing the extent of bone and soft-tissue tumors.     

Magnetic resonance tomography of the bone marrow for the detection of metastases of solid tumors]

The bone marrow is a common site of metastases in patients with solid tumors. Metastatic bone marrow involvement is found much more frequently at autopsy than in routine staging procedures. The purpose of this study was to evaluate the diagnostic efficacy of bone marrow MRI in such patients, and especially in those with small cell lung cancer and female breast carcinoma. MRI is a fast and reliable method for the early detection of bone marrow metastases in patients with carcinoma. In many studies and according to our own experience, it is much more sensitive than radionuclide bone scan, iliac crest biopsy and plain film radiography. However, a clear clinical benefit of its use in the initial staging has so far been proven only for patients with small cell lung cancer. As a consequence, MRI should be applied for the staging of solid tumors only when clinical examination does not yield unambiguous results. Owing to its superiority to biopsy and bone scan, bone marrow MRI should become an integral part of the initial staging procedure in small cell lung cancer and wherever it is sufficiently available it can replace the conventional diagnostic procedures.     

转移性骨肿瘤漏误诊原因的影像学分析

目的 分析转移性骨肿瘤漏、误诊的原因,提高对该病影像诊断水平。材料与方法 回顾分析资料完整的转移性骨肿瘤１０５例,其原发肿瘤主要为肺癌、前列腺癌、消化道癌及乳等。所有病例均摄Ｘ线平片,其中ＣＴ检查３１例,ＭＲ检查２１例,ＥＣＴ检查３４例。结果 骨转移瘤以多发、溶骨型为主。初次影像检查漏、误诊分别为：Ｘ线平片３５例,ＣＴ５例,ＭＲ及ＥＣＴ各１例。结论 影像检查首选ＥＣＴ和Ｘ线平片,有条件时最好作ＣＴ     

Initial results in the assessment of multiple myeloma using 18F-FDG PET

This prospective study was undertaken to investigate the appearance of multiple myeloma on fluorine-18 fluorodeoxyglucose positron emission tomography (FDG-PET). Furthermore, the accuracy of FDG-PET in detecting myeloma lesions and its influence on patient management were evaluated. Forty-three patients with known multiple myeloma (n=28) or solitary plasmacytoma (n=15) underwent FDG-PET. The results of routinely performed radiographs and of scans obtained using all available imaging modalities (MRI, CT), as well as the clinical course, were used for verification of detected lesions. Focally increased tracer uptake was observed in 38 of 41 known osteolytic bone lesions (sensitivity 92.7%) in 23 patients. In addition, 71 further bone lesions which were negative on radiographs were detected in 14 patients. Twenty-six (36.6%) of these lesions could be confirmed in ten patients. As a result of FDG-PET imaging, clinical management was influenced in five (14.0%) patients. The positive predictive value for active disease was 100% in patients with focal or mixed focal/diffuse skeletal FDG uptake and 75% in patients with diffuse bone marrow uptake. Depending on the interpretation of the PET scans in patients with diffuse bone marrow uptake, the sensitivity ranged from 83.8% to 91.9% and the specificity from 83.3% to 100%. FDG-PET thus proved highly accurate in detecting multiple myeloma, and revealed a greater extent of disease than routine radiographs in 14 of 23 (60.9%) patients who had osteolytic bone lesions. FDG-PET might contribute to the initial staging of solitary plasmacytoma.     

Comparative study of fluorodeoxyglucose positron emission tomography and magnetic resonance imaging for the detection of spinal bone marrow infiltration in untreated patients with multiple myeloma

Background: The presence and extent of osteolytic bone lesions in untreated patients with multiple myeloma are important factors in the staging of the disease, and the extent of bone lesions in multiple myeloma cases significantly influences decisions regarding therapy. Recently, fluorodeoxyglucose positron emission tomography (FDG-PET) and magnetic resonance imaging (MRI) have been used to detect bone marrow involvement in patients with multiple myeloma.

Purpose: To compare the efficacy of FDG-PET and MRI for the detection of bone marrow infiltration into the spine in untreated patients with multiple myeloma.

Material and Methods: Twenty-two patients with multiple myeloma underwent both FDG-PET and spine MRI. The examined spinal regions by MRI included 21 thoracic and lumbar spines, one lumbar spine, and 12 cervical spines. The following imaging sequences were performed: T1-weighted spin-echo MRI with and without fat suppression, and T2-weighted spin-echo MRI in the sagittal plane. In the patients with bone marrow abnormalities, an additional contrast-enhanced T1-weighted spin-echo MR image and a fat-suppressed T1-weighted spin-echo MR image were obtained. Patients were divided into three groups on the basis of the criteria defined by Durie and Salmon: stage I (n=9), stage II (n=3), and stage III (n=10). The number and location of lesions detected in both FGD-PET and MRI were recorded, and the lesions were compared using the McNemar test. Bone marrow biopsy results, the patient's clinical examinations, and other imaging findings (MRI, FDG-PET, etc.) were used as references.

Results: In stages I and II (37 lesions in 12 patients), FDG-PET and MRI detected lesions in 78% (29 of 37 lesions) and 86% (32 of 37 lesions), respectively. However, the difference between the abilities of FDG-PET and MRI to detect lesions was not statistically significant (P=0.317). In stage III (101 lesions in 10 patients), FDG-PET and MRI detected lesions in 80% (81 of 101 lesions) and 92% (93 of 101 lesions), respectively. The difference between the abilities of FDG-PET and MRI to detect lesions was statistically significant (P=0.038).

Conclusion: MRI is superior to FDG-PET in detecting bone marrow involvement in the spine of patients with advanced multiple myeloma.     

PET-CT in der nuklearmedizinischen Diagnostik des multiplen Myeloms

Background

Functional or morphofunctional imaging modalities are used in myeloma patients for the diagnosis and therapy management within research protocols. Despite new staging criteria, which take into account the viability of a myeloma lesion, positron emission tomography (PET) is not used routinely.

Objectives

The impact of PET is therefore open. The role of PET and PET computed tomography (PET-CT) for the diagnosis and therapy management is discussed.

Results

The use of PET with 18F-fluorodeoxyglucose (FDG) allows the measurement of viable myeloma lesions and correlates with the stage of disease. A negative FDG examination correlates with a better prognosis. Furthermore, the number of focal lesions as well as the whole functional volume of myeloma lesions in FDG have a prognostic impact. Several studies have demonstrated the impact of FDG for the assessment of therapy monitoring and show that FDG is an earlier indicator for therapy response as compared to magnetic resonance imaging (MRI). The CT component of the new hybrid systems allows the assessment of osteolytic lesions in CT and their viability in FDG. The combination of PET with an MRT scanner allows the simultaneous measurement of bone marrow infiltration, focal lesions and their viability.

Conclusion

The use of modern hybrid scanners, such as PET-CT and PET-MRT facilitates the simultaneous measurement of viable myeloma lesions, osteolytic lesions and bone marrow infiltration in the whole body; therefore, it is expected that these imaging modalities will play a greater role both in diagnosis and therapy management.     

State of the art imaging of multiple myeloma: Comparative review of FDG PET/CT imaging in various clinical settings

18-Flurodeoxyglucose Positron Emission Tomography with computed tomography (FDG PET/CT) and Magnetic Resonance Imaging (MRI) have higher sensitivity and specificity than whole-body X-ray (WBXR) survey in evaluating disease extent in patients with multiple myeloma (MM). Both modalities are now recommended by the Durie–Salmon Plus classification although the emphasis is more on MRI than PET/CT. The presence of extra-medullary disease (EMD) as evaluated by PET/CT imaging, initial SUV_max and number of focal lesions (FL) are deemed to be strong prognostic parameters at staging. MRI remains the most sensitive technique for the detection of diffuse bone marrow involvement in both the pre and post-therapy setting. Compression fractures are best characterized with MRI signal changes, for determining vertebroplasty candidates. While PET/CT allows for earlier and more specific evaluation of therapeutic efficacy compared to MRI, when signal abnormalities persist years after treatment. PET/CT interpretation, however, can be challenging in the vertebral column and pelvis as well as in cases with post-therapy changes. Hence, a reading approach combining the high sensitivity of MRI and superior specificity of FDG PET/CT would be preferred to increase the diagnostic accuracy. In summary, the established management methods in MM, mainly relying on biological tumor parameters should be complemented with functional imaging data, both at staging and restaging for optimal management of MM.     

Diffuse bone marrow uptake on F-18 FDG PET in patients with myelodysplastic syndromes

It is well known that hematopoietic cytokine stimulation can cause diffuse increase of FDG accumulation in bone marrow on PET imaging, which simulates that seen in patients with bone marrow metastases. However, diffuse bone marrow FDG uptake can be caused by other etiologies. We report 2 patients who did not have a history of hematopoietic cytokine stimulation. The FDG PET images showed diffuse bone marrow FDG uptake, and the patients were diagnosed as having myelodysplastic syndromes. These cases demonstrate that diffuse FDG uptake by bone marrow can suggest neoplastic disease of the hematopoietic tissues.     

Light chain deposition disease in multiple myeloma: MR imaging features correlated with histopathological findings

The clinical, histopathological, and imaging findings on MRI of a 56-year-old woman with light chain deposition disease occurring in multiple myeloma are presented. Light chain deposition disease is a variant of multiple myeloma with distinct clinical and histological characteristics. MRI of this patient also revealed an infiltration pattern in the bone marrow distinct from that of typical multiple myeloma. Multiple small foci of low signal intensity were present on T1- and T2-weighted spin echo and STIR images, corresponding to conglomerates of light chains in bone marrow biopsy. Contrast-enhanced T1-weighted spin echo images show diffuse enhancement of 51% over all vertebral bodies, with a minor enhancement of the focal conglomerates of light chains. Light chain deposition disease in multiple myeloma should be added to the list of those few entities with normal radiographs and discrete low-signal marrow lesions on T1- and T2-weighted spin echo pulse sequences.     

全身MRI与PET/CT在淋巴瘤骨髓浸润诊断及预后中的作用

淋巴瘤是一种血液系统恶性肿瘤。淋巴瘤骨髓浸润(BMI)使疾病分期上升至IV期, 是疾病进展、预后较差的标志。常规部位的骨髓活检(BMB)具有创伤性, 且检出率低。PET/CT与全身MRI的出现, 丰富了BMI的检测手段。PET/CT与全身MRI对于淋巴瘤, 尤其是侵袭性淋巴瘤BMI均具有较高的检出率, 二者孰高孰低, 尚未定论。对于红骨髓、良性骨髓病变(炎症等)、淋巴瘤BMI病灶以及肿瘤治疗后骨髓的变化与骨髓残留或复发病灶, 全身MRI很难区分, 而PET/CT却可以很好地鉴别这些病灶。但是, PET/CT存在电离辐射; 对于惰性淋巴瘤的BMI, 超出PET/CT分辨率的病灶, 可能出现假阴性; 某些情况会限制PET/CT的使用, 包括18F-FDG生理性摄取量可能发生改变的正常组织、18F-FDG摄取相关性炎症、高血糖或高胰岛素血症导致的18F-FDG分布的改变、肿瘤患者治疗后出现的骨髓活化等。然而, 这些情况可以使用全身MRI。因此, 全身MRI和PET/CT相辅相成, 优势互补, 但二者均不能代替BMB。对于常规BMB阴性, 但影像学提示阳性的患者, 在影像学引导下进行BMB, 可以提高BMI的检出率。另外, 全身MRI阳性的淋巴瘤BMI患者与全身MRI阴性的淋巴瘤BMI患者相比, 前者预后可能较差。     

Disseminated sarcoidosis involving lymph nodes,bone and spleen with progressive cardiac sarcoidosis on 18F-FDG PET/CT and cardiac MRI

A 63-year-old lady with a background of ischemic heart disease was referred for ¹⁸F-FDG PET/CT for multiple lytic bone lesions which showed disseminated FDG avid lesions in the skeleton, nodal stations as well as spleen simulating advanced malignancy such as diffuse lymphomatous disease. A diagnosis of sarcoidosis was pathologically confirmed with bone biopsy. Following treatment, repeat PET/CT revealed significant regression of FDG avid lesions, however prominent uptake in the lateral ventricular wall was suspicious for active cardiac sarcoidosis, particularly given recurrent chest pain. This was confirmed on cardiac MRI and correlation with PET enabled discrimination between ischemic and non-ischemic fibrosis.     

骨肉瘤病的影像学诊断

目的分析骨肉瘤病的影像学表现，评价影像学的诊断价值。方法总结分析15例骨肉瘤病的影像学特点。15例均行平片检查，其中13例行CT检查，11例行发射型计算机体层摄影(ECT)检查，5例行MR检查。4例行DSA造影检查。结果15例中骨肉瘤病主病灶位于股骨远端者8例，胫骨近端5例，肱骨近端1例，锁骨1例。主病灶之外的多发病灶发生在股骨远端者6例，其中双侧病变2例。位于胫骨近端者8例，骨盆2例，脊柱椎体6例，颅骨1例，髂骨及骶髂关节4例，双侧股骨近端3例，胫骨远端2例。15例主要病变X线表现为典型骨肉瘤样，而发生在其他部位的病灶表现不同，多呈圆形成骨样改变。13例CT观察到病变范围分布及软组织肿块的情况；其中发生在骨髓病变区内的病变多为边缘清楚的高密度瘤骨，5例病变在MRI呈圆形信号改变。特别是髓腔内低信号的骨化区域显示得很清楚。11例ECT检查者可见呈全身分布的广泛浓聚区域。4例于DSA可观察到肿瘤血管边界及肿瘤血管的走行。结论骨肉瘤病为全身的多发病灶，影像学检查可观察全身发病的部位、表现，对疾病的诊断和治疗将提供可靠的依据。